影响非瓣膜性心房颤动患者达比加群或华法林药物治疗持续性的因素。
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.
作者信息
Annavarapu Srinivas, Gandhi Pranav K, Li Yong, Arora Prachi, Moretz Chad, Wang Cheng, Sander Stephen D, Andrews George A
机构信息
Comprehensive Health Insights, Louisville, KY 40202, USA.
Boehringer Ingelheim, Ridgefield, CT 06877, USA.
出版信息
J Comp Eff Res. 2018 Jul;7(7):685-691. doi: 10.2217/cer-2017-0081. Epub 2018 May 29.
UNLABELLED
Factors influencing differences in persistence between dabigatran and warfarin in patients with nonvalvular atrial fibrillation (NVAF) remain unclear.
AIM
Compare differences in persistence between new dabigatran and warfarin users in patients newly diagnosed with NVAF, adjusting for sociodemographics, clinical characteristics, patient out-of-pocket cost and other covariates.
METHODS
A retrospective matched-cohort study was conducted using a US claims database of Medicare and commercially insured patients with NVAF aged≥ 18 years. Persistence and monthly out-of-pocket costs for dabigatran or warfarin were calculated and adjusted for covariates using Cox proportional hazard models.
RESULTS & CONCLUSION: Unadjusted persistence was significantly lower among dabigatran users (n = 1025) compared with matched warfarin users (38 vs 46%). Adjusting for covariates rendered this difference insignificant (hazard ratio = 0.930).
未标注
非瓣膜性心房颤动（NVAF）患者中，达比加群和华法林在持续用药方面存在差异的影响因素仍不明确。
目的
比较新诊断为NVAF的患者中，新使用达比加群和华法林的患者在持续用药方面的差异，并对社会人口统计学、临床特征、患者自付费用及其他协变量进行调整。
方法
利用美国医疗保险和商业保险的≥18岁NVAF患者索赔数据库进行一项回顾性匹配队列研究。计算达比加群或华法林的持续用药情况和每月自付费用，并使用Cox比例风险模型对协变量进行调整。
结果与结论
与匹配的华法林使用者相比，达比加群使用者（n = 1025）未经调整的持续用药率显著较低（38%对46%）。对协变量进行调整后，这种差异变得不显著（风险比 = 0.930）。
Zotero 插件